Tempest Therapeutics, Inc. (TPST) is a pioneering clinical-stage biotechnology company that is committed to discovering and developing first-in-class therapeutics that bolster the immune response to defeat cancer. Their revolutionary approach to cancer treatment has positioned them at the forefront of the industry and made a significant impact on cancer patients worldwide.
Founded in 2016 and based in South San Francisco, California, their primary goal is to develop novel therapeutics that modify tumor cell metabolism and tumor immune evasion, providing new treatment options that will change the life of patients suffering from cancer. With a voracious passion for unraveling cancer's complexities and a cohesive team of leading experts in the field, Tempest is continuously advancing our understanding of these deadly diseases.
Tempest Therapeutics' standout programs such as TPST-1120, TPST-1495, and TPST-8844 have opened up brand-new pathways for future cancer treatments. Their TPST-1120 is a first-in-class antagonist of the enzyme PPARα, with the potential for broad use across many types of cancer. The product TPST-1495 is a dual antagonist of EP2/4 that reverts immunosuppressive mechanisms in tumors, thus enabling the body's immune system to recognize and efficiently eliminate cancer cells.
Moreover, the company's cornerstone technology harnesses the full power of the immune system to recognize and kill cancer cells more efficiently. They leverage strong partnerships with leading researchers and clinicians to ensure they're at the cutting-edge of cancer therapeutics research.
Tempest Therapeutics is publicly traded on the NASDAQ under the ticker symbol TPST. Since its initial public offering (IPO) in June 2021, it has managed to attract substantial attention from investors owing to its impressive pipeline of promising therapeutics.
The company represents a beacon of hope for patients with cancer, working tirelessly to bring their innovative therapies to the public. With their robust portfolio of candidates and strategic partnerships, Tempest Therapeutics has positioned itself for long-term success in the fight against cancer. They remain committed to their mission of driving innovation to provide new answers and hope for patients and their families deeply affected by this pervasive disease. In summary, Tempest Therapeutics exemplifies the power of modern scientific ingenuity applied to one of humanity's most persistent health challenges.